Monopar Therapeutics (NASDAQ:MNPR) Releases Earnings Results, Beats Expectations By $0.10 EPS

Monopar Therapeutics (NASDAQ:MNPR) announced its earnings results on Thursday. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.10, FiscalAI reports.

Monopar Therapeutics Price Performance

NASDAQ:MNPR traded down $0.80 during mid-day trading on Friday, reaching $71.89. The stock had a trading volume of 115,622 shares, compared to its average volume of 202,930. The company has a market capitalization of $482.35 million, a price-to-earnings ratio of -33.13 and a beta of 1.62. Monopar Therapeutics has a 1-year low of $50.07 and a 1-year high of $124.82. The stock’s 50 day simple moving average is $83.52 and its two-hundred day simple moving average is $77.40.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on MNPR shares. Barclays restated an “overweight” rating and set a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. HC Wainwright reiterated a “buy” rating on shares of Monopar Therapeutics in a research note on Thursday. Morgan Stanley reissued an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a research report on Monday, August 17th. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, October 15th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Monopar Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $122.78.

Monopar Therapeutics News Summary

These are some of the MNPR news items that stood out recently:

• Positive Sentiment: Cantor Fitzgerald upgraded MNPR from “Neutral” to “Overweight” and set a $119 price target, signaling a more bullish view of the company’s prospects. Cantor Fitzgerald upgrade
• Positive Sentiment: Monopar reported a third-quarter loss of $0.72 per share, narrower than analysts’ $0.82-per-share loss estimate—a modest earnings beat. Third-quarter results and business updates
• Neutral Sentiment: HC Wainwright reiterated its “Buy” rating and forecast losses of $0.91, $1.05, $1.19 and $1.15 per share for 2027’s first through fourth quarters, respectively. The estimates indicate continued losses but do not include a reported change in its rating.

Insider Transactions at Monopar Therapeutics

In other Monopar Therapeutics news, Director Christopher Starr sold 8,400 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $78.50, for a total transaction of $659,400.00. Following the sale, the director owned 5,173 shares in the company, valued at $406,080.50. This represents a 61.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim Tsuchimoto sold 2,891 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $71.26, for a total value of $206,012.66. Following the transaction, the director directly owned 1,199 shares in the company, valued at approximately $85,440.74. This represents a 70.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 51,920 shares of company stock worth $4,527,913. 9.70% of the stock is owned by corporate insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.